Kymera Therapeutics, Inc.
KYMR
$117.39
$2.972.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 11.59% | 20.40% | -5.85% | -7.26% | -16.82% |
| Total Depreciation and Amortization | 0.40% | -0.49% | -5.44% | 3.12% | 1.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.11% | 6.99% | -28.97% | 31.40% | 13.55% |
| Change in Net Operating Assets | 67.07% | -702.54% | -83.66% | 2,523.76% | 104.94% |
| Cash from Operations | 39.14% | -33.10% | -146.21% | 54.73% | 24.34% |
| Capital Expenditure | -8.99% | -309.43% | 41.44% | 73.96% | -48.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 114.41% | 63.88% | -67.70% | -487.24% | 23.70% |
| Cash from Investing | 114.03% | 63.78% | -67.62% | -492.03% | 23.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.59% | -2.16% | 0.72% | -9.69% | -37.91% |
| Issuance of Common Stock | -22.61% | -97.47% | 1,797.21% | -83.78% | 45,901.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -23.18% | -97.34% | 1,684.91% | -83.92% | 95,142.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.79% | -187.23% | 209.50% | -190.66% | 912.05% |